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Growing concern over the spread of resistance to antibiotics and other antimicrobials has
prompted a plethora of recommendations for its control. Strategic programs for resis-
tance containment have been initiated in various countries, particularly in Western
Europe and North America. The World Health Organization and the European Union
have responded to the need for international action by publishing guidance and
encouraging collaboration. These recommendations rightly focus on controlling resis-
tance in the community. They agree on the importance of surveillance of resistance
patterns and antibiotic usage and the need to encourage judicious antibiotic usage
(especially through education of prescribers and the public). Yet there remains a pressing
need for the implementation of effective actions to address these issues. Important
considerations given less attention include infection prevention (e.g. through immuniza-
tion), the use of rapid diagnostic tests to reduce antibiotic usage, audit of implemented
actions, and the provision of feedback. Furthermore, research is necessary to ﬁll the
substantial gaps in our knowledge. Notably, the reversibility or containment of resistance
with the optimization of antibiotic usage has yet to be deﬁnitely established. For now,
antimicrobial management programs should focus on ensuring the most appropriate use
of antimicrobials rather than simply on limiting choices. Finally, developed countries
must recognize that a truly global approach to resistance containment will require greater
support for developing countries.
Keywords Antimicrobial resistance, resistance management, national, international
programs, audit, guidelines
INTRODUCTION
Resistance to antibiotics is increasingly common
among bacteria responsible for a variety of infec-
tions, including respiratory tract infections (RTIs) in
the community [1]. Growing concern about this
problem and its implications for human health
haspromptednumerousbodies to issue recommen-
dations for resistance control. Strategic intervention
programs for controlling the spread of resistance
havebeenimplementedatthenational level,andtoa
lesser extent the international level, during the past
decade. This paper is Part 1 of a two-part review of
the process of moving from recommendation to
implementation and audit. It aims to look across
the major published recommendations and pro-
grams tooutline theirmaincommonfeatures.Given
the importance of international co-operation, it
focuses in particular on the recent international
efforts of the European Union (EU) and the World
Health Organization (WHO). The paper highlights
theachievementsmadebynationalprogramstodate
and also where gaps remain in the recommenda-
tions, in theactions implemented,and inourcurrent
knowledge. Part 2 of this two-part discussion
reviews the process of audit and the evidence-base
for the effectiveness of speciﬁc interventions [2].
NATIONAL STRATEGIC PROGRAMS
National strategic programs for the control of
resistance to antimicrobials have been initiated
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in various countries (Tables 1 and 2). In Europe,
these efforts include the National Action Plan for
Control of Bacterial Resistance to Antibiotics in
France, the Swedish Strategic Program for the
Rational Use of Antimicrobial Agents and Surveil-
lance of Resistance (STRAMA), the UK Antimicro-
bial and Resistance Strategy and Action Plan, the
MIKSTRA program in Finland, the Danish Inte-
grated Antimicrobial Resistance Monitoring and
Research Program (DANMAP), and the Belgian
Antibiotic Policy Co-ordination Committee.
In the USA, the Centers for Disease Control and
Prevention (CDC) have collaborated with nine
other federal agencies, including the Food and
Drugs Administration and the National Institutes
of Health, to form the Interagency Task Force on
Antimicrobial Resistance. This group published
Part 1 of its Public Health Action Plan to Combat
Antimicrobial Resistance, focusing on domestic
actions, in 2001 [3]. This ambitious document
acknowledges that achievements in resistance con-
trol to date have been insufﬁcient. It recognizes the
considerable challenges facing all nations, stating
that:
‘. . .controlling antimicrobial resistance re-
quires sustained effort, commitment and col-
laboration among many groups in the public
and private sectors, and involvement of the
general public. It also requires support and
leadership from the federal government and a
willingness to address complex and some-
times controversial scientiﬁc, medical and
economic issues’ [3].
In common with many other published recom-
mendations, the Interagency Task Force takes a
broad-based approach to controlling resistance to
all antimicrobials (i.e. those active against bacteria,
viruses, fungi, etc.). It deﬁnes a series of goals and
national actions focusing on surveillance, preven-
tion and control, research, and product develop-
ment. For each action, the co-ordinating and
collaborating organizations involved are named
and broad timelines for initiation (stretching over
5 years) are given. Implementation of the plan will
be incremental, contingent upon resources, and
hence 13 ‘Top Priority Action Items’ are high-
lighted.
In Canada, the Canadian Committee on Anti-
microbial Resistance (CCAR) has been formed to
implement the ‘Integrated Action Plan for Cana-
dians on Controlling Antimicrobial Resistance’.
There have been relatively few co-ordinated
national efforts to control resistance in LatinAmer-
ica, Asia, Africa and Japan. However, in Australia,
a report by the Joint Expert Technical Advisory
Committee on Antimicrobial Resistance resulted
in the setting-up of an Antibiotic Resistance Mon-
itoring (ARM) program that is to be initiated and
co-ordinated by the Expert Advisory Group on
Antimicrobial Resistance (EAGAR).
A detailed analysis of these and other national
resistance control recommendations and pro-
grams is beyond the scope of this article. Such
reviews have been published elsewhere [4,5]. Most
notably, a comprehensive review by the Alliance
for the Prudent Use of Antibiotics [5] has recently
been published by the WHO as a background
document to its Global Strategy for the Contain-
ment of Antimicrobial Resistance [6]. In addition,
readers are urged to visit the ofﬁcial websites of
national recommendations and programs to
obtain further details (Table 3). Additional infor-
mation is also available from the website of the
International Forum on Antibiotic Resistance
(http://www.ifar.net).
The main target for these national programs is
usually resistance in the community outpatient
setting. This is because around 80% of antibiotic
usage occurs in the community. Speciﬁc, local
programs for the control of resistance have been
undertaken in numerous university or general
hospitals in many countries. Hospitals represent
a ‘micro’ ecological system in which microbiologic
surveillance of resistance, control of antibiotic
prescribing, and the provision of feedback to pre-
scribers regarding the impact of interventions to
control resistance are relatively easy. Considerable
challenges remain in controlling resistance in hos-
pitals, despite this relative ease. However, the
effectiveness of interventions combining transmis-
sion control (hygiene) and antibiotic usage control
has been demonstrated in several hospitals. These
have been successful in numerous very speciﬁc
conditions, as measured by decreased antibiotic
use and reduction in resistance rates. For instance,
limiting third-generation cephalosporin use has
been shown to reduce the prevalence of extend-
ed-spectrumb-lactamase-producingKlebsiella pneu-
moniae and vancomycin-resistant enterococci [7].
In contrast, the community setting represents a
‘macro’ system containing a large number of rela-
tively isolated prescribers who are difﬁcult to
reach. Prescriptions for antibiotics in the commu-
nity are, in the vast majority of cases, purely
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Table 1 Summary of influential recommendations for the control of antimicrobial resistance
Surveillance Optimizing antibiotic use Education Prevention
Recommendation
Antibiotic
usage
Resistance
rates
Diagnostic
testing
Treatment
guidelines Professional Public
Infection
control
Immuni-
zation
National
Australia: Commonwealth Govt/JETACAR/EAGAR (1998–2000) H H H H H H
Belgium: Belgian Antibiotic Policy Co-ordination Committee (1998) H H H H H
Canada: Working Group Recommendations (1997) H H H H H
Canada: Health Canada/CIDS: Controlling Antibiotic Resistance
Conference (1996)
H H H H H
France: National Programme for Control of Dissemination of
Multiresistant Bacilli (1998)
H H H H H H H H
France: National Action Plan for Control of Bacterial Resistance
to Antibiotics (1999)
H H H H H H H H
Finland: MIKSTRA (1998) H H H H H
Sweden: National Board of Health and Welfare (2000) H H H H
Sweden: STRAMA (1996) H H H H H H
UK: Department of Health: Antimicrobial Resistance Strategy and
Action Plan (2000)
H H H H H H H
UK: National Health Service (1999) H H H H H H
UK: House of Lords: Resistance to Antibiotics and other
Antimicrobial Agents (1998)
H H H H H H H
UK: SMAC: the Path of Least Resistance (1998) H H H H H
USA: CDC/Interagency Task Force (2001) H H H H H H H H
USA: Infectious Disease Society of America (2000) H H H H H
USA: Center for Science in the Public Interest (1998) H H H H H H H
USA: Institute of Medicine Forum on Emerging Infections (1998) H H H
USA: American Society of Microbiology: Report of the ASM Task
Force on Antibiotic Resistance (1994)
H H H H H H
International
Europe: Community Strategy Against Antimicrobial Resistance
(2001)
H H H H H H H H
Europe: Copenhagen Recommendations (1998) H H H H H H
Summit on Antimicrobial Resistance (39th ICAAC) (1999) H H H
Toronto Declaration (2000) H H H
WHO: Global Strategy for Containment of Antimicrobial
Resistance (2001)
H H H H H H H H
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Table 2 Summary of influential recommendations for the control of antimicrobial resistance
Industry Regulatory Audit Other
Recommendation
Industry
involvement
Drug
development
Central
prescribing
restriction
Advert
restriction
Evaluation
of
intervention
Audit of
compliance
Physician
feedback R & D
International
co-operation
National
Australia: Commonwealth Govt/JETACAR/EAGAR
(1998–2000)
H H
Belgium: Belgian Antibiotic Policy Co-ordination
Committee (1998)
H
Canada: Working Group Recommendations (1997) H H
Canada: Health Canada/CIDS: Controlling Antibiotic
Resistance Conference (1996)
H
France: National Programme for the Control of
Dissemination of Multiresistant Bacilli (1998)
H H H H H H H H H
France: National Action Plan for Control of Bacterial
Resistance to Antibiotics (1999)
H H H H H H H H H
Finland: MIKSTRA (1998) H H H
Sweden: National Board of Health and Welfare 2000 H H H
Sweden: STRAMA (1994) H
UK: Department of Health: Antimicrobial
Resistance Strategy and Action Plan (2000)
H H H H
UK: National Health Service (1999) H
UK: House of Lords: Resistance to Antibiotics and
other Antimicrobial Agents (1998)
H H H H H H
UK: SMAC: the Path of Least Resistance (1998) H H H
US: CDC/Interagency Task Force (2000) H H H H H
US: Infectious Disease Society of America (2000 H H
US: Center for Science in the Public Interest (1998) H H H
US: Institute of Medicine Forum on Emerging
Infections (1998)
H H H H
US: American Society of Microbiology: Report of the
ASM Task Force on Antibiotic Resistance (1994)
H H
International
Europe: Community Strategy Against Antimicrobial
Resistance (2001)
H H H H
Europe: Copenhagen Recommendations (1998) H H H H
Summit on Antimicrobial Resistance (39th ICAAC)
(1999)
H H
Toronto Declaration (2000) H
WHO: Global Strategy for Containment of
Antimicrobial Resistance (2001)
H H H H H H H
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Table 3 Links to official websites providing details of influential recommendations and strategic programs for the control of antimicrobial resistance or other relevant
information
Country Organization/program/document Website
National
Australia Joint Expert Advisory Committee on Antibiotic Resistance (JETACAR) http://www.health.gov.au/pubhlth/
strateg/jetacar
Belgium Belgian Antibiotic Policy Co-ordination Committee (BAPCOC) http://www.antibiotiques.org
Canada Integrated Action Plan for Canadians on Controlling Antimicrobial Resistance http://www.ccar-ccra.org
Denmark Danish Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP) http://www.svs.dk/dk/Organization/z/
forsider/danmap forsider.htm
France National Observatory of the Epidemiology of Bacterial Resistance to Antimicrobials (ONERBA) http://www.onerba.org
Agence Nationale d’Accre´ditation et d’Evaluation en Sante´ (ANAES) http://www.anaes.fr
Agence Franc¸aise de Se´curite´ Sanitaire des Produits de Sante´ (AFSSAPS) http://www.afssaps.sante.fr
Institut National de Veille Sanitaire (INVS) http://www.invs.sante.fr
Finland MIKSTRA http://www.stakes.fi/mikstra/e/
Sweden Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance
of Resistance (STRAMA)
http://www.strama.org
United Kingdom Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance: ‘the Path of
Least Resistance’
http://www.doh.gov.uk/smac1.htm
United States Centers for Disease Control and Prevention (CDC): Public Health Action http://www.cdc.gov/drugresistance/
Plan to Combat Antimicrobial Resistance actionplan/
Infectious Disease Society of America (IDSA) http://www.idsociety.org
Alliance for the Prudent Use of Antibiotics (APUA) http://www.apua.org
American Society for Microbiology (ASM) http://www.asm.org
International
Europe European Antimicrobial Resistance Surveillance System (EARSS) http://www.earss.rivm.nl
European Commission: Communication from the Commission on a http://www.europa.eu.int
Community Strategy Against Antimicrobial Resistance
European Society for Clinical Microbiology and Infectious Diseases (ESCMID) http://www.escmid.org
Scientific Evaluation on the Use of Antimicrobial Agents in Human http://www.uia.ac.be/esac/
Therapy (ESAC)
Global
International Forum on Antibiotic Resistance (IFAR) http://www.ifar.net
International Society for Infectious Diseases (ISID) http://www.isid.org
World Health Organization (WHO): Global Strategy for Containment of http://www.who.int/emc/amr.html
Antimicrobial Resistance
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empiric and issued without previous cultures or
other microbiologic diagnostic tests. Also, as
Davey et al. have reviewed elsewhere in this sup-
plement [8], community physicians are subject to
various pressures to prescribe antibiotics (e.g.
from patients, health systems, physician’s own
concerns regarding infective complications, and
potentially from inappropriate pharmaceutical
industry marketing), even in situations that do
not require them.Thus, comprehensive,nationwide
programs are needed to overcome the development
and spread of resistance in the community.
INTERNATIONAL STRATEGIES
Resistant bacteria do not recognize geographical
boundaries and, as a result of international travel
and trade, the threat they pose is a truly global
health-care problem. Therefore, in addition to local
and national programs, concerted international
strategies to control bacterial resistance are
urgently required. The fruits of international dis-
cussions have culminated during the last year in
the publication of guidance documents from the
EU [9,10] and the WHO [6]. The CDC is also
expected to publish Part II of its Public Health
Action Plan, focusing on global issues, in 2002.
European Union
The EU has attempted to address the issue of
antimicrobial resistance through a wide range of
initiatives. The breadth and scope of the initiatives
outlined below illustrate the political will of the EU
to tackle the problem. Although the EU has limited
powers in terms of health-care delivery, action at
this level is crucial.
The EU conference on ‘The Microbial Threat’,
held in Copenhagen in 1998, marked one of the
ﬁrst attempts to deﬁne Europe-wide recommen-
dations to address the issue of antimicrobial resis-
tance. This meeting resulted in the publication of
the Copenhagen Recommendations (Table 4). In
addition, other bodies such as the Economic and
Social Committee [11], the Consumer Committee
[12], and the Scientiﬁc Steering Committee Opi-
nion on Antimicrobial Resistance [13] published
similar recommendations emphasizing the need
for an integrated EU-wide policy and a multidis-
ciplinary approach to the problem.
In response to these recommendations, in June
1999 the Council of the EU adopted a resolution on
antimicrobial resistance entitled ‘A Strategy
Against the Microbial Threat’ [14]. This resolution
urged the EU Member States to promote national
programs for the prevention and control of infec-
tious diseases, speciﬁcally to include: the reduc-
tion of the risk of human infection through
vaccination and information campaigns; tight con-
trols on the sale, supply and distribution of anti-
microbial agents; and the creation of best-practice
guidelines on prudent antimicrobial use in human
and veterinary medicine. The Council stressed the
need for a multidisciplinary and cross-sectorial
approach, for an overall strategy, and for co-ordi-
nated action. This was followed by the adoption of
a conclusion paper in December 1999, in which the
Council also invited the Commission to widen the
principle of restricting the use of antimicrobial
agents in human or veterinary medicine or in
animal feed or plant production [15]. In May 2001,
the Scientiﬁc Steering Committee onAntimicrobial
Resistance re-endorsed its recommendations of
1999 [13] and encouraged the European Commis-
sion to act urgently upon these recommendations.
In June 2001, ameeting entitled ‘Progress Report
on Antimicrobial Resistance’ (held in Visby,
Sweden) served as a follow-up to the Copenhagen
Table 4 Recommendations from the European Union conference on ‘the Microbial Threat’, held in Copenhagen in 1998
(the Copenhagen Recommendations 1998)
The EU and Member States must recognize that antimicrobial resistance is a major European and global problem.
The EU and Member States should set up a European surveillance system of antimicrobial resistance.
The EU and Member States need to collect data on the supply and consumption of antimicrobial agents.
The EU and Member States should encourage the adoption of a wide range of measures to promote prudent use of
antimicrobial agents.
The EU, Member States, and national research councils should make co-ordinated research on antimicrobial resistance a
high priority.
Pharmaceutical companies should be encouraged to develop new antimicrobial agents.
A way should be found to review progress with these recommendations and proposals.
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Conference of 1998. There was a consensus at this
meeting that the Copenhagen Recommendations
remained valid and that they should be broadly
implemented. While many countries have taken
actions as a direct result of the 1998 meeting [4],
there was some disappointment that progress had
not been sufﬁciently rapid [16]. Among the recom-
mendations from the Copenhagen meeting that
were reinforced in Visbywere: the implementation
of educational initiatives for health professionals
and the general public; the distribution of antibio-
tics by prescription only; the introduction of anti-
microbial teams in every hospital (to cover
primary and secondary care); the introduction of
guidelines for appropriate antimicrobial usage in
all aspects of both medical and veterinary practice;
and the need for increased access to diagnostic
testing.
These meetings, involving EU decision-makers
and scientists, culminated in a communication
from the Commission regarding a Community
StrategyAgainst Antimicrobial Resistance [9]. This
strategy proposes the following four key areas for
action.
 Surveillance: monitoring the evolution and the
effects of interventions through the establish-
ment/strengthening of accurate surveillance
systems on antimicrobial resistance in the
human and veterinary sector and the consump-
tion of antimicrobial agents.
 Prevention: prevention of communicable dis-
eases and infection control to reduce the needs
for antimicrobial agents.
 Research and product development: new mod-
alities for prevention and treatment of infection
and continued support for research into new
drugs and alternatives.
 International co-operation: an effective strategy
requires close co-operation and consultation
between the Commission, the EUMember States
and other involved parties, especially at interna-
tional level.
The ﬁrst three of these priorities concur with
those deﬁned by the US domestic Public Health
Action Plan to Combat Antimicrobial Resistance
[3], which also acknowledges the importance of
global collaboration.
Togetherwith itsCommunityStrategy, theCoun-
cil of the EU proposed Recommendations on the
Prudent Use of Antimicrobial Agents in Human
Medicine [10]. The strategy and recommendations
were ofﬁcially adopted by the November 2001
Health Council. The European Parliament recently
responded to these recommendations [17].
Although theParliament recognized theworthiness
of the Council’s recommendations, it emphasized
the need for amorewide-ranging, global strategy to
address the fact that antimicrobial agents also enter
humans through the food chain via their use in
veterinary medicine, animal rearing and crop culti-
vation. Furthermore, the European Parliament
recommended that the effectiveness, and hence
necessity, of routine preventive use of antimicrobial
agents (e.g. to prevent surgical infection) should be
evaluated, as should the effectiveness of vaccines.
Thus, the Council Recommendations [10] and
the European Commission Communication [9]
represent the ﬁrst attempts of European Commu-
nity-level action regarding antibiotic use in human
medicine. These actions will be complemented
and co-ordinated with existing measures designed
to address veterinary and agricultural uses of
antimicrobial drugs. The European Agency for
the Evaluation of Medicinal Products (EMEA)
has convened an ad hoc group of experts to provide
a risk assessment regarding antimicrobial resis-
tance in veterinary medicine through the Commit-
tee for Veterinary Medicinal Products. This group
will also consider ways of managing antimicrobial
resistance in veterinary medicine with a view to
reducing the risk of transfer to humans. Actions
already initiated by the corresponding EMEA
scientiﬁc Committee for Medicinal Products for
Human Use (CPMP) are listed below.
 The introduction of a guideline to industry and
regulatory assessors regarding the preparation
of product information given to health profes-
sionals upon the introduction of new antibiotics.
The guideline speciﬁes the provision of infor-
mation on acquired bacterial resistance and
the need for manufacturers to update this
information.
 The inclusion in the European Public Assess-
ment Report (EPAR) of information on the num-
ber and characteristics of patients making up the
database on the prevalence of resistance in the
EU. This report also includesmethods for setting
breakpoints for relevant antibiotic/pathogen
combinations where appropriate.
 The publication of a ‘Points to Consider’ docu-
ment on the use of pharmacokinetics and phar-
macodynamic principles in establishing
optimum dosing schedules in the development
of new agents.
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Another example of Europe-wide activity is
the EU-funded Antibiotic Resistance—Prevention
and Control (ARPAC) initiative. ARPAC is a
multidisciplinary 3-year study of the development
of strategies for control and prevention of anti-
biotic resistance in European hospitals. The project
was conceived by the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID)
in response to the Copenhagen Recommenda-
tions of 1998 [18] and involves the collaborative
effort of four ESCMID Study Groups (Table 5).
Its aims are to identify antibiotic policies and
prescription patterns associated with lower resist-
ance rates and infection-control policies associated
with a low incidence of organisms of partic-
ular concern. ARPAC expects to make recommen-
dations regarding optimal measures to control
resistance and to stimulate intervention studies.
Further information regarding the project is
available via the ESCMID website (http://www.
escmid.org). Although the ARPAC project is lim-
ited to the hospital setting, it serves as testament
to the political will within the EU to address the
problem of antimicrobial resistance and it may
represent a model for future research in the com-
munity.
World Health Organization
The WHO has a unique role in raising awareness
of bacterial resistance to antibiotics and in co-
ordinating action to control the problem, at the
global level. The wider issue of antimicrobial resis-
tance was the focus of the WHO Report on Infec-
tious Diseases published in 2000 [19]. In the
opening statement of that report, Dr Gro Harlem
Brundtland, Director-General of the WHO,
emphasized the need for
‘a global strategy to contain resistance and . . .
alliances involving all health-care provi-
ders—countries, governments, international
organizations, nongovernmental organiza-
tions and both the private and public
health-care sectors.’
The WHO duly took a leadership role by pub-
lishing its own comprehensive Global Strategy for
the Containment of Antimicrobial Resistance in
2001 [6]. This document was developed after
wide-ranging international consultation with all
sectors involved, including infectious-disease
practitioners, professional and scientiﬁc societies,
national governments, industry representatives,
consumer groups, and veterinary groups. It
focuses particularly, though not exclusively, on
resistance to antibacterial drugs with the stated
aim being ‘to provide . . . a framework of interven-
tions to stimulate the prevention of infection, to
slow the emergence of resistance and to reduce the
spread of resistant micro-organisms, to reduce the
impact of resistance on health and health-care
costs, while improving access to existing agents
and encouraging the development of new agents’.
The numerous interventions recommended are
grouped under the following six key areas:
 reducing the disease burden and spread of resis-
tance;
 improving access to appropriate antibiotic ther-
apy;
 improving antibiotic use;
 strengthening health-care systems and their sur-
veillance capacities;
 enforcing regulations and legislation;
Table 5 Roles of the European Society of Clinical Microbiology and Infectious Diseases Study Groups within the
collaborative Antibiotic Resistance—Prevention and Control (ARPAC) studya
Study group Role
European Study Group on Antimicrobial
Resistance Surveillance (ESGARS)
Compile an inventory of antibiotic resistance data and development of a
strategy for collection, collation, critical assessment, and dissemination of
resistance data
European Study Group on Antibiotic
Policies (ESGAP)
Compile an inventory of antibiotic consumption, prescribing habits, policies
and stewardship in European hospitals
European Study Group on Nosocomial
Infections (ESGNI)
Compile an inventory of European hospital policies and practices for
controlling transmissible antibiotic-resistant micro-organisms
European Study Group on Epidemiological
Markers (ESGEM)
Develop a DNA typing database and data exchange format for tracking
epidemic antibiotic-resistant micro-organisms
aFurther information is available at http://www.escmid.org
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 encouraging the development of appropriate
new antibiotics and vaccines.
Althoughmost of the interventions in the Global
Strategy concern interventions in human medi-
cine, the document incorporates the recommen-
dations of a working party on the use of
antimicrobials in animals.
While the WHO Global Strategy stresses the
importance of concerted international actions, it
also offers guidance on the implementation of the
speciﬁc interventions at a national level. Given the
spectrum of possible interventions, the guidance
provided on how they may be prioritized accord-
ing to the health-care situation of individual coun-
tries might prove particularly useful. For example,
with regard to bacterial RTIs, the WHO Global
Strategy gives the highest priority to interventions
that tackle misuse of antibiotics for human med-
icine in the community, exploit the potential of
vaccines, and improve surveillance of antibiotic
resistance. It also outlines models for the imple-
mentation of core interventions and the assess-
ment of this process.
COMMENTARY
Clearly, various recommendations regarding the
control of bacterial resistance have been issued by
national scientiﬁc societies and health authorities
during the past decade. In addition, international
bodies such as the WHO and the EU have shown
their commitment to addressing the problem and
to developing policies for the optimal use of anti-
microbial agents. Generally, the goals of these
recommendations are to deliver general rules on
key components of national and international stra-
tegies, to encourage actions at different levels, and
to clarify responsibilities for implementation and
co-ordination of efforts converging towards the
control of extension of resistance. In view of the
complexity of the problem, the recommendations
encourage a multifaceted approach. While the
various recommendation publications share com-
mon aspects, limitations still exist in their content
and application.
Commonalities and gaps
The main features of many of the most inﬂuential
recommendations and programs designed to
combat bacterial resistance are summarized in
Tables 1 and 2. There is uniform agreement on
the importance of surveying resistance patterns
and antibiotic usage. These activities are essential
to deﬁne the scale of the problem of bacterial
resistance and to assess the impact of strategies
implemented for its containment. The various
authorities are also in agreement regarding the
need to encourage judicious usage of antibiotics.
This can be encouraged through a variety of inter-
ventions aimed at prescribers, dispensers,
patients, parents and health-care systems [2]. In
particular, existing recommendations and pro-
grams uniformly encourage the use of treatment
guidelines and the development of education pro-
cesses for prescribers and the public.
All of these measures are considered essential
elements of any successful program. Their bene-
ﬁts, and the challenges inherent in their applica-
tion, are discussed in more detail in other sections
within the Global White Paper on Bacterial Resis-
tance in Community-Acquired Respiratory Tract
Infections [1,8,20]. It is important to stress that,
despite the consensus on their importance, much
progress is required in their effective implementa-
tion. Pressing issues include the difﬁculty in estab-
lishing standardized microbiological surveillance
systems and in effectively inﬂuencing the prescrib-
ing behavior of physicians and the attitudes of
patients regarding antibiotics.
While the recommendations and programs
agree on many aspects of resistance control, some
important considerations are not included in all
recommendations and strategic programs. These
considerations are described below.
 Actions to help reduce antibiotic needs in
humans by preventing infections, e.g. active
immunization against major pathogens invol-
ved in community-acquired RTIs—the major
source of antibiotic use. The pathogens against
which vaccination has a role at present are Strep-
tococcus pneumoniae, Haemophilus inﬂuenzae, in-
ﬂuenza A and B viruses, and respiratory
syncytial virus.
 Actions to reduce antibiotic usage. In particular,
the use of rapid diagnostic tests that can help
physicians to identify quickly when bacteria are
responsible for infections and therefore when an
antibiotic prescription is appropriate. For
instance, the use of a rapid antigen test for the
detection of group A streptococci in patients
with pharyngitis has been shown to increase
signiﬁcantly the number of patients appro-
priately treated [21]. Also, rapid detection of
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 92–106
100 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
pregnant females harboring group B strepto-
cocci prior to delivery has been shown to select
efﬁciently those patients who should be treat-
ed with antibiotics [22]. In both cases, reduction
of antibiotic use is associated with a preser-
vation of the quality of care. In the future, the
further development and usage of these and
other tests—allowing not only rapid detec-
tion of bacteria but also antibiotic resistance
genes [23]—appears to be an essential part
of programs designed to control bacterial resis-
tance.
 Processes for auditing the implemented actions
to establish their effectiveness are not always
considered within the recommendations and
programs. Methods similar to those used in
clinical trials should be considered [2].
 Feedback to prescribers, to help them modify
their practices in agreement with the conclu-
sions of former experiences, is seldom men-
tioned. Also, feedback to politicians in charge
of health policies should be considered more
often.
 Crucially, the promotion of further research
to improve our knowledge is not part of all
programs.
Addressing the major gaps that remain in our
knowledge of infectious diseases and the complex-
ities of resistance development and spread are
necessary to improve the design of programs for
resistance control [24]. We need tools for phar-
maco-epidemiologic studies. For example, we
require better information on the epidemiology
of the most common infections encountered in
children and adults, including the incidence/pre-
valence, presentation, percentage of treated
patients, type of treatment given, impact of envir-
onmental factors, and the socioeconomic impact of
these infections. We also need to investigate the
modalities of antibiotic prescription in the com-
munity, i.e. current prescribing strategies, percen-
tage of failures, overall outcome, etc. In addition,
we need to understand the inﬂuence of modiﬁca-
tions to health-care systems and access to care on
the management and outcome of common infec-
tions to take these parameters into account in the
analysis of the differences observed between coun-
tries, in terms of antibiotic prescribing and bacter-
ial resistance. This information would also aid the
interpretation of difﬁculties encountered in setting
up intervention programs and the analysis of their
effectiveness. These relationships must be better
established through intervention or case–control
studies, both in the community and in hospitals.
At a more basic level, investigations on the rela-
tionships between resistance and virulence (invivo
expression of different genes by resistant bacteria),
and the mechanisms through which bacteria can
acquire resistance from the host ﬂora in vivo,
shouldbe encouraged. In addition, there are several
basic aspects of the dynamics of bacterial resistance
that are poorly understood. Strategies andmethods
are urgently required to measure the impact of
antibiotic resistance on human mortality and mor-
bidity andother health outcomes, as discussed else-
where in this Global White Paper [25]. Studies are
also needed to assess the impact of social factors on
antibiotic efﬁcacy and the development of resis-
tance. In addition, it is important to consider how
individual countries can help control infectious dis-
eases through social programsdesigned to improve
living conditions. Finally, as we will see in the
followingsection,wehaveyet toestablish the extent
to which resistance is reversible when antibiotic
usage decreases. Hence, strategies to control resis-
tancemustnotfocussolelyonprudentantibioticuse,
butmustadoptamultifacetedapproachbasedonan
improved understanding of the mechanisms of
resistance.
Significant achievements and limitations
Some national resistance control programs have
already provided signiﬁcant advances and contri-
butions to our understanding of the challenge of
resistance control. For example, the Canadian pro-
gram, the objective of which was to reduce inap-
propriate antibiotic use by 25% within 3 years,
insists not only on the need for adequate surveil-
lance, but also on conditions that will successfully
change the therapeutic behavior of prescribers and
the public [26]. The British ScientiﬁcMedical Advi-
sory Committee also stressed the importance of
modifying these behaviors and proposes a discus-
sion around the contradictory economic implica-
tions for industry of such policies, i.e. increased
needs of research vs. fewer resources generated by
sales [27]. In the United States, the CDC started
educational strategies and recommended inter-
ventions, together with measurement of their
impacts on costs, antimicrobial usage, and resis-
tance [28].
Although the principles of resistance control
have been established and are broadly agreed
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upon by existing programs, the implementation of
actions to control resistance remain limited. One
obstacle regarding implementation is that the pro-
blem of resistance tends to be viewed in its totality,
i.e. without any hierarchy of priority being applied
to the various actions to be undertaken. Some of
the actions envisaged have a social—and therefore
political—impact that makes their prioritization
even more difﬁcult. In many countries, politicians
may not be convinced of the long-term threat
presented by the extension of bacterial resistance
in terms of morbidity, mortality and extra costs.
This underscores the need for further research in
this area [25].
In some countries, governments have encour-
aged economic initiatives, such as total (Iceland) or
partial (Denmark) nonreimbursement of antibio-
tics. Others have implemented actions towards
prescribers (and sometimes patients) to reduce
antibiotic expenses, as in Australia [29], Iceland
[30], Sweden [31], Finland [32], USA [28] and
France [33]. All of these experiments have been
successful in achieving a decrease in antibiotic
usage, at least over the timeframe of the study,
compared with the pre- and post-intervention
periods. Reductions in antibiotic usage have been
achieved for a range of compounds. However, no
long-term follow-up assessment has been per-
formed to measure the persistence of these effects
once the intervention has stopped or to identify
which types of antibiotic substitutions have
occurred in prescribing practice. Furthermore,
the cost-effectiveness of these interventions has
not been measured in any country.
An example of the care required when imple-
menting centrally driven means of control was
provided in Australia. The Australian Health
Insurance Commission attempted to control the
prescription of coamoxiclav by writing to prescri-
bers stating that this compound was over-pre-
scribed and threatening to conduct an audit.
This led to an undesirable switch to two other
well-publicized antibiotics. The clinical andmicro-
biologic impact of this switch is still being inves-
tigated, but clearly this intervention proves that a
given intervention does not necessarily translate
into a reduction of overall costs and might also
have a negative impact on clinical outcome [29].
Efforts to control antibiotic prescribing are all
based on the assumption that this will reduce,
contain, or at least slow, the development and
spread of bacterial resistance. Certainly, the direct
relationship between the development and exten-
sion of resistance and increased antibiotic use has
been reasonably well established [34–37], although
its dynamics remain unclear (e.g. regarding a
possible threshold level of antibiotic use that trig-
gers resistance or the inﬂuence of different dosage
regimens and lengths of treatment). The crucial
issue in this regard is that the direct demonstration
of the reversibility of bacterial resistance following
decreased antibiotic use has still to be achieved
using randomized trials or epidemiologic inter-
ventions. Evidence to support this link can be
found in three studies.
Firstly, a Finnish study demonstrated a decline
in erythromycin resistance in group A streptococci
when erythromycin consumption was decreased
[32]. However, one should note that the parallel
occurrence of the two phenomena does not neces-
sarily imply a causal relationship. Also, the ban on
erythromycin use induced a shift towards the
newer macrolides, which could be associated with
a potential secondary increase in macrolide resis-
tance among group A streptococci. This study
shows the limitations of actions focused on a single
type of drug.
The second study comes from Iceland, where a
rapid rise in penicillin-resistant pneumococci was
observed between 1989 and 1993. A program of
interventions focused on the overuse of antibiotics
in children was implemented between 1991 and
1997 [30,38,39]. The interventions consisted of a
publicity campaign aimed at consumers and
mediated via newspapers, radio and television,
and a prescriber education program. The result
was a reduction in antibiotic consumption, parti-
cularly of cotrimoxazole andmacrolides, mainly in
children. Subsequently there was a decline in
pneumococcal resistance rates. A concurrent leg-
islation change, instituted primarily for economic
reasons, abolished government subsidies for anti-
biotics. However, this intervention had only a
limited and short-lived effect largely on the most
expensive antimicrobials. Establishing a quantita-
tive relationship between the frequency of resis-
tance and the volume of drug use is difﬁcult
without a simultaneous comparator and without
close attention being paid to circulating genotypes
of pneumococci to disclose spontaneous modiﬁca-
tions of the epidemiology of the bacterium.
Most recently, the Amelioration of Use of b-
lactamsandPneumococcalResistance toPenicillinG
Epidemiological Intervention (AUBEPPIN) Study
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in France has provided direct, controlled evi-
dence that optimizing antibiotic usage can
reduce the spread of resistance [40]. This trial
compared antibiotic usage and oropharyngeal car-
riage rates of penicillin-resistant S. pneumoniae in
children attending day-care centers within three
geographically distinct populations. One popula-
tion (Group 1) was subjected to educational inter-
ventions (aimed at parents, physicians and
pharmacists) designed to reduce antibiotic use
for upper RTIs. These interventions included the
use of rapid diagnostic tests for group A strepto-
coccal pharyngitis. Another population (Group 2)
was subjected to similar interventions designed to
improve the dosage and duration of antibiotic
therapy for RTIs. Suboptimal dosages and pro-
longed treatment durations (>5 days) with b-lac-
tam antibiotics have been associated with an
increased risk of pharyngeal carriage of penicil-
lin-resistant S. pneumoniae [41], while high-dose,
short-course treatment regimens appear to mini-
mize this risk [42]. Finally, a control population
(Group 3) received no intervention at all. During
the 5-month study, antibiotic sales fell by 37% in
Group 1 and by 32% in Group 2, as compared with
Group 3. Furthermore, statistically signiﬁcant
monthly reductions in the rate of colonization with
penicillin-resistant S. pneumoniaewere seen in both
intervention groups (Figure 1).
Actions to control bacterial resistance should be
started on the basis of scientiﬁc studies designed to
demonstrate the reversibility or containment of
resistance with the optimization of antibiotic
usage. Thus, further intervention studies and
case–control studies are necessary for this pur-
pose. These should measure carefully the deﬁned
end-points, e.g. quantities of antibiotics used, qua-
litative information (e.g. type of drug, dose, dura-
tion), and prevalence of resistance among major
pathogens. Clinical trials designed to deﬁne the
minimum duration of antibiotic treatment would
also be worthwhile. Prescribers should be actively
involved in the design of such studies and should
receive feedback to aid the establishment of new
practices. Mathematical models, such as those
developed to predict the extension of resistance
as antibiotic use increases, are potentially useful in
investigating the effects of reducing antibiotic use
[43].
The community setting should be the major
target for actions to reduce resistance. Commu-
nity-acquired RTIs represent the major source
of antibiotic prescribing in the community and
20–50% of antibiotic usage for these conditions
is unnecessary. For example, analysis of data from
the US National Ambulatory Medical Care Survey
(1998) indicate that antibiotic prescriptions in
excess of the number expected to treat bacterial
infections amounted to 55% (22.6 million) of all
antibiotics prescribed for acute RTIs [44]. It is thus
possible to reduce the volume of antibiotic usage
without altering the quality of care. The objective
must also be to optimize antibiotic usage by imple-
menting actions to reduce the duration of therapy
and to encourage the use of optimal doses, in
Figure 1 Results from the Amelioration of Use of
b-lactams and Pneumcococcal Resistance to Penicillin G
Epidemiological Intervention (AUBEPPIN) Study in
France [40]. This 5-month study was conducted in children
attending kindergartens within three geographically dis-
tinct populations. One population (Group 1) was subjected
to educational interventions designed to reduce antibiotic
use for upper respiratory tract infections (including the use
of rapid diagnostic tests for group A streptococcal
pharyngitis), one population (Group 2) was subjected to
similar interventions designed to improve the dosage and
duration of antibiotic therapy for these infections, and the
other population (Group 3) received no intervention at all.
(a) Decrease in antibiotic sales in Groups 1 and 2 compared
with Group 3. (b) Regression coefficient for monthly
reduction in rate of oropharyngeal colonization with
penicillin-resistant Streptococcus pneumoniae (PRSP) in each
group.
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agreement with the pharmacokinetic/pharmaco-
dynamic properties of each drug. Antimicrobial
drug management typically focuses on controlling
costs and controlling bacterial resistance. How-
ever, the selection of therapeutic alternatives
without adherence to a well-developed and evi-
dence-based rationale may promote antimicrobial
resistance and may produce cost shifting rather
than cost containment [45], as we have seen in
Australia [29]. Essentially, antimicrobial manage-
ment programs should focus on ensuring the most
appropriate use of antimicrobials rather than sim-
ply on limiting choices. With regard to the funda-
mental intervention of education, we need to
develop active collaboration between medical pro-
fessionals, patient representatives, and experts in
behavioral changes (e.g. psychologists and sociol-
ogists) [8].
The pharmaceutical industry has a major role to
play in resistance control.We should consider how
to develop relationships between industry and
drug licensing agencies for better deﬁnition of
drug development and marketing policies. An
intensiﬁed dialog should be developed with the
pharmaceutical industry to facilitate research to
develop new antibiotics and alternatives to anti-
biotic therapy. These discussions should also aim
to improve the quality of preclinical studies of
antibiotics, with special attention paid to the
potential for selection for resistance. The role
played by industry in controlling the way new
antibiotics are used and the associated ecological
consequences is also an area for concern [46].
Finally, none of the above mentioned programs
considers the contribution of developed countries
to helping the developing world, in terms of qual-
ity control of antibiotics, marketing approval pro-
cedures, drug delivery (including the avoidance of
over-the-counter delivery), public hygiene, and
education of physicians, pharmacists, and the pub-
lic [6,47]. The motivations for this type of aid are
both altruistic and practical. Populations in devel-
oping regions suffer the greatest impact of infec-
tious diseases and yet have the least access to
antibiotic therapy. Poor socioeconomic conditions
play a crucial but largely unmeasured role in
resistance emergence and spread. Various forms
of antibiotic misuse, by health-care providers and
patients, are more likely to occur in these situa-
tions. These include inappropriate antibiotic usage
(often because of minimal controls on antibiotic
distribution), the use of insufﬁcient or substandard
antibiotic therapy, and poor patient compliance
[47]. To compound the problem, developing
regions often lack the resources and infrastructure
necessary for effective resistance control. It must
be emphasized that emerging resistance in devel-
oping regions also threatens developed regions, as
a consequence of the ease of modern travel. There-
fore truly global co-operation is essential for the
overall containment of resistance in both devel-
oped and developing countries.
CONCLUSIONS
Antimicrobial resistance is one of the most impor-
tant public health concerns of modern times.
National recommendations for the control of bac-
terial resistance to antibiotics are in place in many
countries and hence no agency can claim ignor-
ance. At the national level, the deﬁnition of prio-
rities is now essential. More co-ordinated
interventions based on published, evidence-based
recommendations should be envisaged. Interven-
tions must be audited for their effectiveness and
cost-effectiveness, using appropriate and mean-
ingful end-points, and the results must be disse-
minated and used to reﬁne recommendations and
interventions. Part 2 of this paper [2] discusses
models for successful intervention and audit.
These programs cannot succeed if they do not
imply the active contribution of health profes-
sionals, politicians, consumers, and the pharma-
ceutical industry. The creation of optimal
conditions for this type of co-operation is of critical
importance [48].
There is also an urgent need for international
harmonization of efforts to control the develop-
ment and spread of resistance. Organizations like
the WHO and EU, with the contribution of scien-
tiﬁc societies, should play a major role in those
processes.
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